ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.322,59
0,91%
S&P 500
5.969,34
0,35%
Dow Jones
44.296,51
0,97%
Euro vs US Dollar
1,0418
0,00%
Bitcoin
98.727,57
-0,31%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ

  6. Vernalis Plc ADS (MM) (VNLS) Börsenkurse

Vernalis Plc ADS (MM)

Vernalis Plc ADS (MM) (VNLS)

NASDAQ
0,00
0,00
(0,00%)
Geschlossen 23 November 10:00PM
Verzögert um 15 Minuten
0,00
0,00
(0,00%)
Nach Börsenschluss: -
Verzögert um 15 Minuten

Professionelle Tools für Privatanleger.

Premium

Wichtige Statistiken und Details

Current Price
-
Gebot
-
Fragen
-
Volumen
-
0,00 Tagesbereich 0,00
0,00 52-Wochen-Bereich 0,00
Handelsende
-
Handelsbeginn
-
Letzte Trade
Letzter Handelszeitpunkt
Durchschnittliches Volumen (3 Mio.)
-
Finanzvolumen
-
VWAP
-

VNLS Neueste Nachrichten

Weitere Nachrichten

Vernalis plc Initiates a Phase I Trial of a Promising New Approach to Treating Obesity and Related Disorders - Including Type II

WINNERSH, England, Dec. 11 /PRNewswire-FirstCall/ -- Vernalis plc (LSE: VERLSE:Nasdaq:LSE:VNLS) today announced that it has started a Phase I trial of V24343, a CB1 antagonist, as a potential...

11 Dezember 2006
PR Newswire (US)

Vernalis plc to Present at the 18th Annual Piper Jaffray Healthcare Conference in New York on November 30, 2006

WINNERSH, England, Nov. 21 /PRNewswire-FirstCall/ -- Vernalis plc (LSE: VER)(NASDAQ:VNLS), a specialty bio-pharmaceutical and drug development company, today announced that Simon Sturge, Chief...

21 November 2006
PR Newswire (US)

Vernalis plc Announces Progress on Its Oncology Hsp90 Programme

WINNERSH, England, Nov. 20 /PRNewswire-FirstCall/ -- Vernalis plc (LSE:VERLSE:Nasdaq:LSE:VNLS), a specialty bio-pharmaceutical and drug development company, today announced that Novartis has...

20 November 2006
PR Newswire (US)

Vernalis to Present at Cowen and Company 7th Annual Global Health Care Conference

WINNERSH, England, Nov. 2 /PRNewswire/ -- Vernalis plc (LSE:VERLSE:Nasdaq:LSE:VNLS), a specialty bio-pharmaceutical and drug development company, today announced that Simon Sturge, Chief...

02 November 2006
PR Newswire (US)

Vernalis plc to Present at UBS Global Life Sciences Conference on September 26, 2006

WINNERSH, U.K., Sept. 20 /PRNewswire-FirstCall/ -- Vernalis plc (LSE:VER) (NASDAQ:VNLS), a specialty bio-pharmaceutical and drug development company, today announced that Simon Sturge, Chief...

20 September 2006
PR Newswire (US)

Vernalis plc Announces FDA Acceptance for Filing of Frova(R) for Short-Term Prevention of Menstrual Migraine

WINNERSH, England, Sept. 20 /PRNewswire-FirstCall/ -- Vernalis plc (LSE:VERLSE:Nasdaq:LSE:VNLS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the...

20 September 2006
PR Newswire (US)

Vernalis Plc: Interim Results for the Six Months Ended 30 June 2006

- Vernalis Delivers on Significant Clinical Milestones and Establishes Commercial Operation - WINNERSH, England, Sept. 12 /PRNewswire-FirstCall/ -- Vernalis plc (LSE:VERLSE:Nasdaq:LSE:VNLS...

12 September 2006
PR Newswire (US)

Endo Pharmaceuticals and Vernalis plc Announce the Filing of the Supplemental NDA for Frova(R) for Short-Term Prevention of Men

CHADDS FORD, Pa. and WINNERSH, U.K., July 19 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals Holdings Inc. (NASDAQ:ENDP) and Vernalis plc (NASDAQ:VNLS) (LONDON: VER) today announced that Endo...

20 Juli 2006
PR Newswire (US)

Vernalis plc to Present at Investor Conferences During June 2006

WINNERSH, England, June 19 /PRNewswire-FirstCall/ -- Vernalis plc (NASDAQ:VNLS)(LSE:VER), a specialty bio-pharmaceutical and drug development company, today announced that Simon Sturge, Chief...

19 Juni 2006
PR Newswire (US)
Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Beweger

Alle Anzeigen
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
PDYNPalladyne AI Corporation
US$ 4,59
(129,50%)
83,07M
QMCOQuantum Corporation
US$ 9,11
(126,62%)
39,48M
NANano Labs Ltd
US$ 8,26
(89,02%)
2,03M
XCURExicure Inc
US$ 18,60
(71,27%)
4,59M
SKKSKK Holdings Limited
US$ 1,75
(59,09%)
107,47M
AMIXAutonomix Medical Inc
US$ 6,21
(-54,07%)
897,51k
CETXCemtrex Inc
US$ 0,1146
(-41,74%)
22,89M
MSWMing Shing Group Holdings Ltd
 5,90
(-35,52%)
417,08k
RMSGReal Messenger Corporation
US$ 3,09
(-26,25%)
305,85k
ENSCEnsysce Biosciences Inc
US$ 0,4414
(-25,49%)
3,93M
ELABElevai Labs Inc
US$ 0,0201
(-0,50%)
415,87M
NVDANVIDIA Corporation
US$ 141,95
(-3,22%)
229,93M
SMCISuper Micro Computer Inc
US$ 33,15
(11,62%)
155,43M
VRPXVirpax Pharmaceuticals Inc
US$ 0,5501
(-6,72%)
154,17M
SOUNSoundHound AI Inc
US$ 8,24
(18,05%)
103,6M

Foren

Foren anzeigen
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

NASDAQ
VNLS
Vernalis
BIT
ACE29
Exchange Traded
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten